

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1755 Selected Articles from This Issue

MCT FIRST DISCLOSURES

- 1757 ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK**
Joanne M. Munck, Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, Roberta Ferraldeschi, Tom D. Heightman, Christopher J. Hindley, Justyna Kucia-Tran, John F. Lyons, Vanessa Martins, Sandra Muench, Christopher W. Murray, David Norton, Marc O'Reilly, Michael Reader, David C. Rees, Sharna J. Rich, Caroline J. Richardson, Alpesh D. Shah, Lukas Stanczuk, Neil T. Thompson, Nicola E. Wilsner, Alison J.-A. Woolford, and Nicola G. Wallis

REVIEWS

- 1769 Hallmarks of RET and Co-occurring Genomic Alterations in RET-aberrant Cancers**
Jacob J. Adashek, Aakash P. Desai, Alexander Y. Andreev-Drakhlina, Jason Roszik, Gilbert J. Cote, and Vivek Subbiah
- 1777 Exosomal Noncoding RNAs in Hepatobiliary Cancer: A Rising Star**
Wangyang Zheng, Daolin Ji, Yongxu Zhou, Liang Yu, Peng Huang, Yuling Zheng, Nanfeng Meng, Hang Wang, Xue Bai, ZiYue Huang, Wangming Chen, Judy W.P. Yam, Yi Xu, and Yunfu Cui

SMALL MOLECULE THERAPEUTICS

- 1789 Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses**
Björn Stratenwerth, Susanne M. Geisen, Yang He, Lea Beltzig, Shana J. Sturla, and Bernd Kaina

- 1800 WNK1 Enhances Migration and Invasion in Breast Cancer Models**
Ankita B. Jaykumar, Ji-Ung Jung, Pravat Kumar Parida, Tuyen T. Dang, Chonlarat Wichaidit, Ashari Rashmi Kannangara, Svetlana Earnest, Elizabeth J. Goldsmith, Gray W. Pearson, Srinivas Malladi, and Melanie H. Cobb
- 1809 Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia**
Lu Zhang, Tianyu Cai, Xiaoyu Lin, Xiaoli Huang, Mai H. Bui, Joshua P. Plotnik, Richard J. Bellin, Emily J. Faivre, Vinitha M. Kuruvilla, Lloyd T. Lam, Xin Lu, Zheng Zha, Weiguo Feng, Paul Hessler, Tamar Uziel, Qi Zhang, Antonio Cavazos, Lina Han, Debra C. Ferguson, Gaurav Mehta, Sriram S. Shanmugavelandy, Terrance J. Magoc, Jenny Rowe, Neal C. Goodwin, Kathleen A. Dorritie, Michael Boyiadzis, Daniel H. Albert, Keith F. McDaniel, Warren M. Kati, Marina Konopleva, and Yu Shen
- 1820 Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer**
Tamara Mirzapiozova, Gang Xiao, Bolot Mambetsariev, Mohd W. Nasser, Emily Miaou, Sharad S. Singhal, Saumya Srivastava, Isa Mambetsariev, Michael S. Nelson, Arin Nam, Amita Behal, Pranita Atri, Markus Muschen, François L.H. Tissot, James Miser, John S. Kovach, Martin Sattler, Surinder K. Batra, Prakash Kulkarni, and Ravi Salgia
- 1836 PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus**
Gabriel B. Mpillá, Md. Hafiz Uddin, Mohammed N. Al-Hallak, Amro Aboukameel, Yiwei Li, Steve H. Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William T. Senapedis, Yosef Landesman, Kay-Uwe Wagner, Nerissa T. Viola, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, and Asfar S. Azmi

TABLE OF CONTENTS

- 1846** **Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent**
Finith Jernigan, Arthur Branstrom, John D. Baird, Liangxian Cao, Mandar Dali, Bansri Furia, Min Jung Kim, Kylie O'Keefe, Ronald Kong, Oscar L. Laskin, Joseph M. Colacino, Mark Pykett, Anna Mollin, Josephine Sheedy, Melissa Dumble, Young-Choon Moon, Richard Sheridan, Tobias Mühlethaler, Robert J. Spiegel, Andrea E. Prota, Michel O. Steinmetz, and Marla Weetall
- 1858** **SLC7A11 Is a Superior Determinant of APR-246 (Eprentapopt) Response than TP53 Mutation Status**
Kenji M. Fujihara, Mariana Corrales Benitez, Carlos S. Cabalag, Bonnie Z. Zhang, Hyun S. Ko, David S. Liu, Kaylene J. Simpson, Ygal Haupt, Lara Lipton, Sue Haupt, Wayne A. Phillips, and Nicholas J. Clemons
- 1868** **Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma**
Daniel A.R. Heisey, Sheeba Jacob, Timothy L. Lochmann, Richard Kurupi, Maninderjit S. Ghotra, Marissa L. Calbert, Mayuri Shende, Yuki Kato Maves, Jennifer E. Koblinski, Mikhail G. Dozmorov, Sosipatros A. Boikos, Cyril H. Benes, and Anthony C. Faber
- 1880** **Hsp90 Inhibitor STA9090 Sensitizes Hepatocellular Carcinoma to Hyperthermia-Induced DNA Damage by Suppressing DNA-PKcs Protein Stability and mRNA Transcription**
Lixia Liu, Yaotang Deng, Zhenming Zheng, Zihao Deng, Jinxin Zhang, Jieyou Li, Manfeng Liang, Xueqiong Zhou, Wenchong Tan, Hongjun Yang, Leonard M. Neckers, Fei Zou, and Xuemei Chen
- 1893** **Potent Synergistic Effect on C-Myc-Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a PIK1 Inhibitor**
Yanqi Xie, Wen Zhang, Lichao Guo, Liliia M. Kril, Kristin L. Begley, Vitaliy M. Sviripa, Xi Chen, Xifu Liu, Eun Y. Lee, Daheng He, Chi Wang, Tianyan Gao, Xiaoqi Liu, B. Mark Evers, David S. Watt, and Chunming Liu
- 1904** **Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway**
Wei Zhang, Ankur S. Bhagwath, Zeeshan Ramzan, Taylor A. Williams, Indhumathy Subramanian, Vindhya Edpuganti, Raja Reddy Kallem, Kerry B. Dunbar, Peiguo Ding, Ke Gong, Samuel A. Geurkink, Muhammad S. Beg, James Kim, Qiuyang Zhang, Aryn A. Habib, Sung-Hee Choi, Ritu Lapsiwala, Gayathri Bhagwath, Jonathan E. Dowell, Shelby D. Melton, Chunfa Jie, William C. Putnam, Thai H. Pham, and David H. Wang
- 1916** **Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia**
Anlai Wang, Zhili Song, Gang Zheng, Celine Nicolazzi, Jonathan R. Fromm, Elvis Shehu, Srimathi Srinivasan, Xueyan Chen, Chen Zhu, Marielle Chiron Blondel, and Francisco J. Adrian
- 1926** **T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer**
Dandan Li, Nicholas Schaub, Theresa M. Guerin, Tashinga E. Bapiro, Frances M. Richards, Vicky Chen, Keyur Talsania, Parimal Kumar, Debra J. Gilbert, Jerome J. Schlomer, Seong-Jin Kim, Rebecca Sorber, Yaroslav Teper, Wendy Bautista, Claudia Palena, Chan-Young Ock, Duncan I. Jodrell, Nathan Pate, Monika Mehta, Yongmei Zhao, Serguei Kozlov, and Udo Rudloff
- ## LARGE MOLECULE THERAPEUTICS
- 1941** **Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses *In Vivo***
Rocio Montes de Oca, Alireza S. Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Krupa Patel, Laura Seestaller-Wehr, Heather Kaczynski, Hong Shi, Eric Dobrzynski, Leslie Obert, Lyuben Tsvetkov, David C. Cooper, Heather Jackson, Paul Bojczuk, Sabrina Forveille, Oliver Kepp, Allan Sauvat, Guido Kroemer, Mark Creighton-Gutteridge, Jingsong Yang, Chris Hopson, Niranjana Yanamandra, Christopher Shelton, Patrick Mayes, Joanna Opalinska, Mary Barnette, Roopa Srinivasan, James Smothers, and Axel Hoos
- 1956** **Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration**
Madeleine K. Ramos, Danielle Mandikian, Lauren N. Sermeño, Anna King, Alecia T. Dent, Jason Ho, Sheila Ulufatu, T. Noelle Lombana, Christoph Spiess, Mary Ann T. Go, Shang-Fan Yu, Amrita V. Kamath, Gregory Z. Ferl, and C. Andrew Boswell
- 1966** **A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade**
John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Retter, Rabih Slim, Tara M. Young, William C. Olson, Gavin Thurston, and Christopher Daly

TABLE OF CONTENTS

- 1977** **Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule**
Elizabeth Pham, Matthias Friedrich, Famke Aeffner, Michael Lutteropp, Natalie F. Mariano, Petra Deegen, Christoph Dahlhoff, Franziska Vogel, Claudia Bluemel, John M. Harrold, Christian Brandl, Natalia Grinberg, Benno Rattel, Angela Coxon, and Julie M. Bailis
- 1988** **Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacinib in Patients with Advanced Solid Tumors**
Michael S. Gordon, John Nemunaitis, Minal Barve, Zev A. Wainberg, Erika P. Hamilton, Ramesh K. Ramanathan, George W. Sledge Jr, Huibin Yue, Susan E. Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, and John H. Strickler
- 1996** **Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin**
Timo A. Lehti, Maria I. Pajunen, Anne Jokilampi, Miikka Korja, Hauke Lilie, Kim Vettenranta, and Jukka Finne
- 2008** **Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics**
Hanine Rafidi, Alberto Estevez, Gregory Z. Ferl, Danielle Mandikian, Shannon Stainton, Lauren Sermeño, Simon P. Williams, Amrita V. Kamath, James T. Koerber, and C. Andrew Boswell

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 2016** **A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas**
Avanthi Tayi Shah, Tej D. Azad, Marcus R. Breese, Jacob J. Chabon, Emily G. Hamilton, Krystal Straessler, David M. Kurtz, Stanley G. Leung, Aviv Spillinger, Heng-Yi Liu, Inge H. Behroozfard, Frederick M. Wittber, Florette K. Hazard, Soo-Jin Cho, Heike E. Daldrup-Link, Kieuhoa T. Vo, Arun Rangaswami, Allison Pribnow, Sheri L. Spunt, Norman J. Lacayo, Maximilian Diehn, Ash A. Alizadeh, and E. Alejandro Sweet-Cordero
- 2026** **ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma**
Kelly E. Henry, Kyeana N. Mack, Veronica L. Nagle, Mike Cornejo, Adam O. Michel, Ian L. Fox, Maria Davydova, Thomas R. Dilling, Nagavarakishore Pillarsetty, and Jason S. Lewis

TARGETING DRUG RESISTANCE

- 2035** **KIT^{low} Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor**
Sudeep Banerjee, Hyunho Yoon, Stephanie Ting, Chih-Min Tang, Mayra Yebra, Alexander T. Wenzel, Huwate Yeerna, Jill P. Mesirov, Robert J. Wechsler-Reya, Pablo Tamayo, and Jason K. Sicklick
- 2049** **Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma**
Kelsey W. Nassar, Jennifer D. Hintzsche, Stacey M. Bagby, Veronica Espinoza, Christophe Langouët-Astrié, Carol M. Amato, Tugs-Saikhan Chimed, Mayumi Fujita, William Robinson, Aik Choon Tan, and Rebecca E. Schweppe
- 2061** **Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells**
Alan P. Lombard, Wei Lou, Cameron M. Armstrong, Leandro S. D'Abronzio, Shu Ning, Christopher P. Evans, and Allen C. Gao

MODELS AND TECHNOLOGIES

- 2071** **Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia *In Vitro* and *In Vivo***
Paul D. Rennert, Fay J. Dufort, Lihe Su, Tom Sanford, Alyssa Birt, Lan Wu, Roy R. Lobb, and Christine Ambrose
- 2082** **Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers**
Brendan Hagerty, T. Norene O'Sullivan, Xianyu Zhang, N. Keith Collins, Wendi Custer Lawrence, Laura L. Bassel, Nathan Pate, Jian Xu, Theresa M. Guerin, Serguei Kozlov, and Christine Alewine

LETTERS TO THE EDITOR


- 2093** **Olaratumab-induced Biomarker Modulation in Sarcomas—Letter**
Vicente Valenti, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, and Ramon Salazar
- 2094** **Olaratumab-induced Biomarker Modulation in Sarcomas—Response**
Javier Martín-Broto, Patrick M. Peterson, Gerard J. Oakley, Matteo Ceccarelli, and Robin L. Jones

TABLE OF CONTENTS

ABOUT THE COVER

This graphic depicts “decreased desmoplasia and increased PD-L1 targetability” after MAPK therapy in a proposed model showing alterations in the tumor microenvironment by activating the immune system and breaking down the stromal components, resulting in a release of cytokines and growth factors, along with a migration of inflammatory cells and macrophages. Read the full article on page 2026.

doi: 10.1158/1535-7163.MCT-20-10-CVR



Molecular Cancer Therapeutics

20 (10)

Mol Cancer Ther 2021;20:1755-2094.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.